Industry News

American Renal Associates Holdings, Inc., a leading national provider of outpatient dialysis services, and Western Nephrology, one of the largest nephrology groups in Colorado, today announced plans to open the Kidney Center of the Rockies in Avon, Colorado. This state-of-the-art outpatient dialysis facility will be the only dialysis center located along the I-70 corridor in the Colorado Mountains between the major cities of Denver, CO and Grand Junction,..."/>
American Renal Associates Holdings, Inc. and Western Nephrology Announce Plans to Open the Kidney Center of the Rockies in the Vail Valley
Tandem Diabetes Care ®, Inc., a medical device company and manufacturer of a family of innovative touchscreen insulin pumps, and TypeZero Technologies, LLC, a digital health and personalized medicine company, today announced that they have entered into a License Agreement allowing Tandem to integrate TypeZero’ s artificial pancreas technology into a next-generation t: slim ® Insulin Pump. TypeZero’ s AP technology includes a series of treat-to-target algorithms..."/>
Tandem Diabetes Care and TypeZero Technologies Announce License Agreement to Accelerate Development and Commercialization of Closed-Loop Artificial Pancreas System
Akorn, Inc., a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release on Thursday, August 4, 2016 outlining the second quarter 2016 results.. In addition, the Company will host a conference call at 10:00 am EDT on the same day to discuss its second quarter 2016 financial results. The dial-in number to access the call is 249-9382 in the U.S. and +1 823-1530 for international callers."/>
Akorn Announces Second Quarter 2016 Earnings Release and Conference Call Information
Aytu BioScience, Inc., a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the publication of the first peer-reviewed journal article demonstrating the clinical utility of the Company's MiOXSYS™ System for assessing the level of oxidative stress in semen as an aid in the diagnosis of infertility in men. The article, titled, "MiOXSYS: a novel method of..."/>
Aytu BioScience Announces Publication of Peer-Reviewed Study Demonstrating the Utlility of MiOXSYS™ in the Assessment of Male Infertility
Semler Scientific, Inc., an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare insurers and physician groups, today announced that it will report second quarter 2016 financial results before the open of U.S. financial markets on July 29, 2016. Doug Murphy-Chutorian, M.D., chief executive officer of Semler, will host a conference call at 11 a.m."/>
Semler to Report Second Quarter 2016 Financial Results and Host Conference Call on July 29, 2016
Masimo announced today that a new study of patients undergoing liver transplantation evaluated the relationship of PVI ® to right ventricular end-diastolic volume and concluded that PVI provided a“ reliable estimate of preload status and may be a useful predictor of fluid responsiveness.” 1 PVI measures the dynamic changes in perfusion index that occur during one or more complete respiratory cycles, using the Masimo pulse oximetry plethsymographic..."/>
New Study Evaluates Masimo PVI® as a Predictor of Fluid Responsiveness in Patients Undergoing Liver Transplantation
INVO Bioscience, Inc., a reproductive medical device company that was granted FDA clearance for the first in vivo, vaginal incubation system, the INVOcell™, today announced UR Medicine's Strong Fertility Center is the first fertility practice in Western and Upstate New York to offer a new alternative to in vitro fertilization– a vaginal incubation system that uses a woman's body, rather than a laboratory, to incubate her..."/>
Strong Fertility Center Introduces INVOcell™ Vaginal Incubation Fertility Option to Western, Upstate New York
Henry Schein, Inc., the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, announced today that it will release its second quarter 2016 financial results before the stock market opens on Thursday, August 4, 2016, and will provide a live webcast of its earnings conference call on the same day beginning at 10:00 a.m. Eastern time. Speakers on the call will include..."/>
Henry Schein To Webcast Second Quarter 2016 Conference Call On Thursday, August 4, 2016, At 10:00 a.m. ET
Omnicell, Inc., a leading provider of medication and supply management solutions and analytics software for healthcare facilities, will hold a conference call Thursday, July 28, 2016, to discuss the Company's second Quarter 2016 financial results. About Omnicell Since 1992, Omnicell has been creating innovative solutions to improve patient care, anywhere it is delivered. Omnicell is a leading supplier of comprehensive..."/>
Omnicell to Release Second Quarter 2016 Earnings Results on July 28th
NxStage Medical, Inc., is pleased to announce the grand opening of its Macon dialysis center, known as Georgia Kidney Institute. "We aim to give patients their autonomy back by providing treatment options to meet each patient's individual needs," stated Dr. R. Ellis, Medical Director of GKI, and joint venture partner."/>
Macon Dialysis Center Grand Opening
PTC Therapeutics, Inc. today announced that the Company will host a webcast conference call to report its second quarter financial results and provide an update on the company's business and outlook on Thursday, August 4, 2016 at 4:30 p.m. after the closing of the market. The call can be accessed by dialing 303-9216 or 935-8152 five minutes prior to the start of the call and providing the passcode 49796148. A live, listen-only..."/>
PTC Therapeutics to Host Conference Call to Discuss Second Quarter Financial Results
AMAG Pharmaceuticals, Inc. today announced it will report unaudited consolidated financial results for the second quarter ended June 30, 2016 before the U.S. financial markets open on Tuesday, August 9, 2016. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET, during which management will provide an update on recent developments and discuss the company’ s second quarter 2016 financial and operating..."/>
AMAG Pharmaceuticals to Host Conference Call on August 9, 2016 at 8:00 a.m. ET to Discuss Financial Results for the Second Quarter Ended June 30, 2016
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the second quarter ended June 30, 2016 before the U.S. financial markets open on Thursday, August 4, 2016.. Management will host a conference call on that date at 10:00 a.m. EDT to discuss these results and provide an update on the company. To access the call, please dial 224-9084 or..."/>
Momenta Pharmaceuticals Announces Date for Second Quarter 2016 Financial Results Conference Call and Webcast
MediWound Ltd., a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announces that the Company will release financial results for the three and six months ended June 30, 2016, at 7:00 a.m. Eastern time on July 28, 2016.. Following the release, MediWound's management will host a conference call for the investment community beginning at 8:30 a.m. ET on..."/>
MediWound to Host Second Quarter 2016 Financial Results Conference Call on July 28, 2016 at 8:30 a.m. Eastern Time
BioPharmX Corporation, a specialty pharmaceutical company developing products for the dermatology market, will share findings from the first comparative studies of oral and topical minocycline formulations, which detected no traces of minocycline in the bloodstream when it is applied topically. BioPharmX conducted two directional comparative pharmacokinetics studies of oral minocycline to topical BPX-01."/>
BioPharmX Study Shows BPX-01 Topical Gel Delivers Minocycline Precisely to the Skin
RepliCel Life Sciences Inc.,, a clinical-stage regenerative medicine company focused on the development of autologous cell therapies, is pleased that its RCH-01 product, for the treatment of androgenetic alopecia, is now cleared by the Japanese regulatory authorities for use in a clinical research study launching now in Japan. The study, designed to involve 60 men and women with thinning hair caused by androgenetic alopecia, will be..."/>
RepliCel's Cell Therapy for Pattern Baldness Proceeds to Clinical Trial Launch in Japan
Bovie Medical, announced a sales channel partnership agreement with Hologic, effective immediately. Hologic will add Bovie’ s J-Plasma ® product line to its world class portfolio of healthcare solutions in gynecological and gynecological/oncological surgery in three U.S. regions. The initial six-month agreement provides certain members of Hologic’ s direct GYN Surgical sales force with access to J-Plasma ® and includes the option to extend the..."/>
Bovie Medical Announces Sales Channel Partnership Agreement with Hologic for J-Plasma®
Spark Therapeutics and Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted breakthrough therapy designation to SPK-9001, the lead investigational candidate in the companies’ SPK-FIX program, in development for the treatment of hemophilia B. SPK-9001, a novel bio-engineered adeno-associated virus capsid expressing a codon-optimized, high-activity human factor IX variant, is being investigated in an..."/>
Spark Therapeutics and Pfizer Announce Receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the Treatment of Hemophilia B
Mylan NV reported on Wednesday the availability of Rosuvastatin Calcium Tablets, 5 mg, 10 mg, 20 mg and 40 mg in the US market. The company stated that the Rosuvastatin Calcium Tablets, 5 mg, 10 mg, 20 mg and 40 mg is the generic version of AstraZeneca's Crestor. According to the company, it has received final approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Rosuvastatin Calcium Tablets, The tablets are used in..."/>
Mylan unveils generic Crestor Tablets for treating high triglycerides
BioCryst Pharmaceuticals, Inc. today announced that its second quarter 2016 financial results will be released on Thursday, August 4, 2016. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update regarding the Company’ s clinical development programs. The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Thomas R. Staab, II, Senior Vice..."/>
BioCryst to Announce Second Quarter 2016 Financial Results August 4
RXi Pharmaceuticals Corporation, a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, announced today that it will present a poster at the 2016 Summer Meeting of the American Academy of Dermatology. This meeting will bring together the best minds in dermatology to be immersed in an innovative program that includes presentations by renowned experts on topics that..."/>
RXi Pharmaceuticals to Present at the 2016 Summer Meeting of the American Academy of Dermatology

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials575 Articles
Consumer Discretionary521 Articles
Information Technology490 Articles
Industrials391 Articles
Health Care309 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at